Anonymous
Guest
Anonymous
Guest
Fierce Pharma Marketing May 18th, 2015:
"A couple of caveats, however. If Pfizer and Bristol-Myers decide to target Xarelto in a share battle, there's a bigger risk of loss for the Bayer and J&J med. Then there's Savaysa, the new entry into the warfarin-alternative market from Daiichi Sankyo. Though it doesn't have much to differentiate it from its rivals, Daiichi could get aggressive with pricing, which would obviously ratchet up the pressure.
Meanwhile, Bayer and J&J continue to build up stats in Xarelto's favor. Over the weekend, the companies announced data from the VENTURE-AF study showing that Xarelto was as safe as warfarin in atrial fibrillation patients undergoing catheter ablation. "Given the dose adjustments often needed for patients on vitamin K antagonists, such as warfarin, to ensure the medicine is working effectively, rivaroxaban may offer a simpler approach in this setting," said the study's lead author, Dr. Andrea Natale, executive medical director at St. David's Medical Center's Texas Cardiac Arrhythmia"
Not looking good for Savaysa.....
You are not kidding. Way to go Edison!